{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:51:04Z","timestamp":1754488264875},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients with multiple myeloma (MM) were excluded from the original SARS-CoV-2 mRNA vaccine trials, which may influence vaccine hesitancy in this population. We prospectively characterized the safety and immunogenicity of two-dose SARS-CoV-2 mRNA vaccination in 44 patients with MM, who underwent vaccination from 12\/17\/2020 to 3\/18\/2021.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Rates adverse reactions were low and consistent with those documented in vaccine trials. Among those on MM therapy, 93% developed detectable anti-receptor binding domain (RBD) antibodies after dose 2, while 94% of patients not on MM therapy seroconverted.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Two-dose SARS-CoV-2 mRNA vaccination is mildly reactogenic and leads to high rates of seroconversion in patients with MM. These findings can provide reassurance to MM patients who are hesitant to receive SARS-CoV-2 mRNA vaccines.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09097-5","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T18:02:39Z","timestamp":1640628159000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma"],"prefix":"10.1186","volume":"21","author":[{"given":"Ross S.","family":"Greenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake A.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Boyarsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Werbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Garonzik-Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorry L.","family":"Segev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip H.","family":"Imus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"issue":"10","key":"9097_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00372-5","volume":"10","author":"J Mart\u00ednez-L\u00f3pez","year":"2020","unstructured":"Mart\u00ednez-L\u00f3pez J, Mateos MV, Encinas C, Sureda A, Hern\u00e1ndez-Rivas J\u00c1, de la Gu\u00eda AL, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J. 2020;10(10):1\u20131.","journal-title":"Blood Cancer J"},{"key":"9097_CR2","doi-asserted-by":"crossref","unstructured":"Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. HemaSphere 2021, 5(3):e547.","DOI":"10.1097\/HS9.0000000000000547"},{"issue":"27","key":"9097_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"key":"9097_CR4","doi-asserted-by":"crossref","unstructured":"Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England J Med. 2020;383(25):2439\u201350.","DOI":"10.1056\/NEJMoa2027906"},{"key":"9097_CR5","doi-asserted-by":"crossref","unstructured":"Connolly CM, Ruddy JA, Boyarsky BJ, Avery RK, Werbel WA, Segev DL, et al. Safety of\u202fthe\u202ffirst\u202fdose of\u202fmRNA SARS-CoV-2\u202fvaccines in\u202fpatients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(8):1100\u20131.","DOI":"10.1136\/annrheumdis-2021-220231"},{"key":"9097_CR6","doi-asserted-by":"crossref","unstructured":"Ou MT, Boyarsky BJ, Motter JD, Greenberg RS, Teles AT, Ruddy JA, et al: Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplant. 2021;105(10):2170\u20134.","DOI":"10.1097\/TP.0000000000003780"},{"key":"9097_CR7","doi-asserted-by":"crossref","unstructured":"Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. Jama. 2021;325(17):1784\u20136.","DOI":"10.1001\/jama.2021.4385"},{"key":"9097_CR8","doi-asserted-by":"crossref","unstructured":"Boyarsky BJ, Ruddy JA, Connolly CM, Ou MT, Werbel WA, Garonzik-Wang JM, et al. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases. Ann Rheum Dis. 2021;80(8):1098\u20139.","DOI":"10.1136\/annrheumdis-2021-220289"},{"key":"9097_CR9","doi-asserted-by":"crossref","unstructured":"Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, et al: Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia. 2021;35(1):31\u201344.","DOI":"10.1038\/s41375-020-01016-0"},{"key":"9097_CR10","doi-asserted-by":"crossref","unstructured":"Bird S, Panopoulou A, Shea RL, Tsui M, Saso R, Sud A, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. Lancet Haematol. 2021;8(6):e389\u2013e392.","DOI":"10.1016\/S2352-3026(21)00110-1"},{"key":"9097_CR11","doi-asserted-by":"crossref","unstructured":"Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137(26):3674\u20136.","DOI":"10.1182\/blood.2021011904"},{"issue":"1","key":"9097_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01025-7","volume":"14","author":"F Pimpinelli","year":"2021","unstructured":"Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. J Hematol Oncol. 2021;14(1):1\u20132.","journal-title":"J Hematol Oncol"},{"key":"9097_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cca.2021.03.007","volume":"518","author":"T Mueller","year":"2021","unstructured":"Mueller T. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological assays from the same manufacturer. Clin Chim Acta. 2021;518:9\u201316.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"9097_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13027-021-00375-2","volume":"16","author":"E Cavalcanti","year":"2021","unstructured":"Cavalcanti E, Isgr\u00f2 MA, Rea D, et al. Vaccination strategy and anti - SARS-CoV-2\u2009S titers in healthcare workers of the INT - IRCCS \u201cFondazione Pascale\u201d Cancer center (Naples, Italy). Infect Agent Cancer. 2021;16(1):32 Published 2021 May 12.","journal-title":"Infect Agent Cancer"},{"key":"9097_CR15","doi-asserted-by":"crossref","unstructured":"Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: a prospective cohort study. Ann Int Med. 2021;174(11):1572\u201385.","DOI":"10.7326\/M21-1757"},{"issue":"18","key":"9097_CR16","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell\u2013redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4(18):4538\u201349.","journal-title":"Blood Adv"},{"issue":"5","key":"9097_CR17","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","volume":"18","author":"K Noonan","year":"2012","unstructured":"Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012;18(5):1426\u201334.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9097_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.exphem.2015.02.005","volume":"43","author":"SM Tete","year":"2015","unstructured":"Tete SM, Kipling D, Westra J, et al. Monoclonal paraprotein influences baseline B-cell repertoire diversity and perturbates influenza vaccination-induced B-cell response. Exp Hematol. 2015;43(6):439\u201347.e1.","journal-title":"Exp Hematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09097-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09097-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T18:03:27Z","timestamp":1640628207000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09097-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["9097"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09097-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Johns Hopkins Institutional Review Board (IRB00248540) and participants provided informed consent electronically. All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.L.S. has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, Thermo Fisher Scientific. The other authors of this manuscript have no financial disclosures or conflicts of interest to disclose as described by <i>BMC Cancer.<\/i>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1354"}}